# US 6,730,315 B2 · Medium and matrix for long-term proliferation of cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,315 B2
- Document ID: US6730315B2
- Status: Granted
- Kind: B2
- Application number: 09/758,676
- Filed: 2001-01-11
- Published: 2001-07-12
- Granted: 2004-05-04
- Earliest claimed: 1992-02-24
- Assignees: Encelle, Inc.
- Inventors: Anton-Lewis Usala; Richard Chris Klann
- Web page: https://patentgrep.com/patent/US6730315B2

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61F 2/022: {Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36)}
- A61L 15/32: Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)}
- A61L 15/44: Medicaments
- A61L 27/222: {Gelatin}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 15/02: for disorders of the vagina
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2035/128: {capsules, e.g. microcapsules}
- A61L 2300/114: Nitric oxide, i.e. NO
- A61L 2300/204: with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L 2300/214: Amino acids
- A61L 2300/236: Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/434: of enzymes
- A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures
- A61L 2300/62: Encapsulated active agents, e.g. emulsified droplets
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A cell culture medium and hydrogel matrix for long term storage and proliferation of cells is provided. The cell culture medium and hydrogel matrix include an effective amount of polar amino acids, the polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid. The cell culture medium comprises about 5 to about 150 mM of polar amino acids. The hydrogel matrix comprises about 3 to about 150 mM of polar amino acids. Arginine and glutamic acid are preferably supplemented in the cell culture medium. Arginine, lysine, and glutamic acid are preferably supplemented in the hydrogel matrix. A method of maintaining viability and functioning of a transplant is also provided. The method of maintaining viability of a transplant includes encapsulating the cells in a hydrogel matrix and injecting the encapsulated cells into the host organism. The matrix of the present invention may also be used to promote vascularization in a transplant site prior to injection of cells.

## Claims

### Claim 1

A hydrogel matrix for long-term storage and proliferation of cellular tissue, consisting essentially of a mixture of:
gelatin;
dextran or sulfated dextxan;
at least one polar amino acid; and
optionally, one or more of intact collagen, an L-arginine analogue, L-cysteine, and a divalent chelator.

### Claim 2 (depends on 1)

A hydrogel matrix according to claim 1, wherein said gelatin is present at a concentration of about 0.01 to about 40 mM.

### Claim 3 (depends on 1)

A hydrogel matrix according to claim 1, wherein said at least one polar amino acid is present in an amount of about 3 to about 150 mM.

### Claim 4 (depends on 3)

A hydrogel matrix according to claim 3, wherein said at least one polar amino acid is present in an amount of about 10 to about 65 mM.

### Claim 5 (depends on 1)

A hydrogel matrix according to claim 1, wherein said at least one polar amino acid is selected from the group consisting of arginine, glutamic acid, lysine and mixtures thereof.

### Claim 6 (depends on 5)

A hydrogel matrix according to claim 5, wherein L-glutamic acid is present at a concentration of about 2 to about 60 mM, L-lysine is present at a concentration of about 0.5 to about 30 mM, and arginine is present at a concentration of about 1 to about 40 mM.

### Claim 7 (depends on 6)

A hydrogel matrix according to claim 6, wherein L-glutamic acid is present at a concentration of about 5 to about 40 mM, L-lysine is present at a concentration of about 1 to about 15 mM, and arginine is present at a concentration of about 1 to about 30 mM.

### Claim 8 (depends on 1)

A hydrogel matrix according to claim 1, wherein the L-cysteine is present at a concentration of about 5 to about 500 μM.

### Claim 9 (depends on 8)

A hydrogel matrix according to claim 8, wherein the L-cysteine is present at a concentration of about 15 to about 25 μM.

### Claim 10 (depends on 1)

A hydrogel matrix according to claim 1, wherein the L-arginine analogue is present at a concentration of about 5 to about 500 μM.

### Claim 11 (depends on 10)

A hydrogel matrix according to claim 10, wherein the L-arginine analogue is present at a concentration of about 15 to about 25 μM.

### Claim 12 (depends on 10)

A hydrogel matrix according to claim 10, wherein said L-arginine analogue is aminoguanidine.

### Claim 13 (depends on 1)

A hydrogel matrix according to claim 1, wherein said at least one polar amino acid is about 10 to about 20 mM of L-glutamic acid.

### Claim 14 (depends on 1)

A hydrogel matrix according to claim 1, wherein said at least one polar amino acid is about 5 to about 15 mM of arginine.

### Claim 15 (depends on 1)

A hydrogel matrix according to claim 1, wherein said at least one polar amino acid is about 1 to about 10 mM of L-lysine.

### Claim 16 (depends on 1)

A hydrogel matrix according to claim 1, wherein the divalent chelator is present at a concentration of about 1 to about 8 mM.

### Claim 17 (depends on 1)

A hydrogel matrix according to claim 1, wherein the intact collagen is present at a concentration of about 0.05 to about 0.5 mM.

### Claim 18 (depends on 1)

A hydrogel matrix according to claim 1, wherein said gelatin is denatured collagen.

### Claim 19 (depends on 1)

A hydrogel matrix according to claim 1, wherein the at least one polar amino acid is selected from the group consisting of arginine, lysine, histidine, glutamic acid, aspartic acid, and mixtures thereof.

### Claim 20 (depends on 1)

A hydrogel matrix according to claim 1, wherein said gelatin is denatured collagen.

### Claim 21 (depends on 20)

A hydrogel matrix according to claim 20, wherein said at least one polar amino acid is selected from the group consisting of arginine, lysine, histidine, glutamic acid, aspartic acid, and mixtures thereof.

### Claim 22 (depends on 20)

A hydrogel matrix according to claim 20, wherein said at least one polar amino acid is selected from the group consisting of arginine, glutamic acid, lysine and mixtures thereof.

### Claim 23

A hydrogel matrix for long-term storage and proliferation of cellular tissue, comprising a mixture of:
gelatin;
dextran or sulfated dextran;
at least one polar amino acid; and
about 1 to about 8 mM of a divalent chelator, the divalent chelator comprising EDTA.

### Claim 24

A hydrogel matrix for long-term storage and proliferation of cellular tissue comprising a mixture of:
denatured collagen;
dextran or sulfated dextran;
an L-arginine analogue; and
at least one polar amino acid selected from the group consisting of arginine, lysine, histidine, glutamic acid, aspartic acid, and mixtures thereof.

### Claim 25 (depends on 24)

A hydrogel matrix according to claim 24, wherein said at least one polar amino acid is present in an amount of about 5 to about 150 mM.

### Claim 26 (depends on 24)

A hydrogel matrix according to claim 24, comprising:
about 2 to about 60 mM of L-glutamic acid;
about 0.5 to about 30 mM of L-lysine; and
about 1 to about 40 mM of arginine.

### Claim 27 (depends on 24)

A hydrogel matrix according to claim 24, wherein said L-arginine analogue comprises aminoguanidine.

### Claim 28 (depends on 24)

A hydrogel matrix according to claim 24, wherein said matrix comprises about 0.01 to about 40 mM of said denatured collagen.

### Claim 29 (depends on 24)

A hydrogel matrix according to claim 24, further comprising about 5 to about 500 μM of L-cysteine.

### Claim 30 (depends on 29)

A hydrogel matrix according to claim 29, wherein said matrix comprises about 15 to about 25 μM of said L-cysteine.

### Claim 31 (depends on 24)

A hydrogel matrix according to claim 24, wherein said matrix comprises about 5 to about 500 μM of said L-arginine analogue.

### Claim 32 (depends on 31)

A hydrogel matrix according to claim 31, wherein said matrix comprises about 15 to about 25 μM of said L-arginine analogue.
